Treatment Of Portal Hypertensive Pulmonary Lesions Induced By Schistosomiasis
Main Category: Tropical DiseasesAlso Included In: Clinical Trials / Drug Trials; Vascular
Article Date: 06 Mar 2010 - 0:00 PDT
| Patient / Public: | ![]() |
1 (3 votes) |
| Healthcare Prof: | ![]() |
To evaluate efficacy of Calculus Bovis compound preparation (ICCBco) in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model, a research group in China performed a randomized, double-blind, controlled trial to observe pathological changes and pathological effect mechanism of expression of fibronectin and laminin in the lung tissue of portal hypertensive rabbits with schistosomiasis.
In vitro cultivated ICCBco is composed of Calculus Bovis, Chinese Paris Rhizome, polygonum cuspidatum, appendiculate cremastra pseudobulb, frankincense, and myrrh, and has the functions of clearing away heat and toxic materials, removing blood stasis, reducing swelling, eliminating blood stasis and promoting tissue regeneration, according to the principle of traditional Chinese medicine. However, the topic has not been unequivocally addressed.
A research article published in the World Journal of Gastroenterology addresses this question. The group led by Tao Li, MD, evaluated the efficacy of ICCBco in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model. They explored the pathogenesis of portal hypertension and the prevention and treatment of its pulmonary complications (hepatopulmonary syndrome, pulmonary fibrosis, pulmonary hypertension, pulmonary venous hypertension) from a new perspective of portal hypertensive vascular disease. Calculus Bovis is a Class 1 new Chinese medicine developed by Wuhan Tongji Hospital with independent intellectual property rights, is a treasure of traditional Chinese medicine. To investigate its role in the treatment of schistosomiasis-induced pulmonary complications of portal hypertension has far-reaching significance.
The successful development of Calculus Bovis and the preliminary study on portal hypertensive pulmonary lesions caused by schistosomiasis suggest that it is of great significance and prospects for further basic and clinical research, development and clinical application of new drugs and preparations to treat portal hypertensive pulmonary lesions induced by schistosomiasis.
Reference: Li T, Yang Z, Cai HJ, Song LW, Lu KY, Zhou Z, Wu ZD. Effects of in vitro cultivated Calculus Bovis compound on pulmonary lesions in rabbits with schistosomiasis. World J Gastroenterol 2010; 16(6): 749-754 http://www.wjgnet.com/1007-9327/16/749.asp
Correspondence to: Tao Li, MD, Department of General Surgery and Oncology, China Mei Tan General Hospital, Beijing 100028, China.
Source:
Jin-Lei Wang
World Journal of Gastroenterology
Visit our tropical diseases section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/181398.php>
APA
http://www.medicalnewstoday.com/releases/181398.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




